Ashley Malone
Family · Ashland, KYNPI 1134766991
Payments from drug & device makers
Across 737 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Inspire Medical Systems, Inc.$661
- Grifols USA, LLC$644
- plus $5K from 28 others
What the payments were for
- Food & beverage$13,32798%
- Education$3002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 193 | $2,804 |
| AstraZeneca | 92 | $1,932 |
| Boehringer Ingelheim | 57 | $1,133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $1,017 |
| Inspire Medical Systems, Inc. | 27 | $661 |
| Grifols USA, LLC | 34 | $644 |
| Mylan Specialty L.p. | 28 | $612 |
| Electromed, Inc. | 41 | $602 |
| Philips North America LLC | 23 | $578 |
| Axsome Therapeutics, Inc. | 28 | $572 |
| Jazz Pharmaceuticals Inc. | 28 | $473 |
| Harmony Biosciences LLC | 25 | $411 |
| Sanofi | 16 | $373 |
| Regeneron Healthcare Solutions, Inc. | 11 | $265 |
| Verona Pharma, Inc. | 8 | $196 |
| Viatris Specialty LLC | 7 | $160 |
| Baxter Healthcare | 7 | $151 |
| Pulmonx Corporation | 5 | $135 |
| Genentech USA, Inc. | 9 | $123 |
| Teva Pharmaceuticals USA, Inc. | 8 | $120 |
| Amgen | 5 | $108 |
| Johnson & Johnson | 6 | $92 |
| Insmed, Inc. | 3 | $69 |
| United Therapeutics Corporation | 4 | $69 |
| Lilly USA, LLC | 4 | $68 |
| Sanofi-aventis U.S. LLC | 1 | $64 |
| Merck | 2 | $33 |
| Inogen, Inc. | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| UCB, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,626 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 356 | $346,780 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $202,283 |
| NucalaMepolizumab | 23 | $84,108 |
| Fasenra PenBenralizumab | 12 | $66,552 |
| Spiriva RespimatTiotropium Bromide | 68 | $60,988 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $47,877 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $31,137 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $30,011 |
| Spiriva HandihalerTiotropium Bromide | 27 | $27,466 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 409 | $16,215 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $12,126 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $11,911 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,752 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $7,640 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $7,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $2,804 | $484,903466 claims |
| Grifols USA, LLCProlastin C | $644 | $202,28313 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,133 | $90,999111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,932 | $67,13790 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Ashland
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.